Literature DB >> 18388870

Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice.

G R Robertson1, C Liddle, S J Clarke.   

Abstract

A tumor-associated inflammatory response has recently been found to contribute to the considerable interindividual variability in cytotoxic drug clearance seen in cancer patients. Circulating inflammatory markers, such as C-reactive protein (CRP) and interleukin-6 (IL-6), correlate with excessive drug toxicity caused by reduced CYP3A4-mediated metabolism. This article outlines the use of a transgenic mouse model of human CYP3A4 regulation to demonstrate that extrahepatic tumors elicit an inflammatory response, leading to transcriptional repression of the CYP3A4 gene as well as of other drug clearance pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18388870     DOI: 10.1038/clpt.2008.55

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

1.  Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes.

Authors:  Jian Yang; Chunshu Hao; Dongfang Yang; Deshi Shi; Xiulong Song; Xiaofei Luan; Gang Hu; Bingfang Yan
Journal:  Toxicol Lett       Date:  2010-06-09       Impact factor: 4.372

2.  DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes.

Authors:  Mao Zhao; Luan Xiaofei; Cao Gang; Liu Wei; Xiong Jing; Hu Gang; Chen Ruini; Ning Rui; Shang Wei; Yang Jian; Yan Bingfang
Journal:  Biochem Pharmacol       Date:  2012-06-21       Impact factor: 5.858

3.  Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate.

Authors:  Fredrik Sjöö; Ibrahim El-Serafi; Jon Enestig; Jonas Mattsson; Johan Liwing; Moustapha Hassan
Journal:  Clin Drug Investig       Date:  2014-01       Impact factor: 2.859

Review 4.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

5.  Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation.

Authors:  Hadi Molanaei; Peter Stenvinkel; Abdul Rashid Qureshi; Juan Jesús Carrero; Olof Heimbürger; Bengt Lindholm; Ulf Diczfalusy; Ingegerd Odar-Cederlöf; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2011-12-09       Impact factor: 2.953

6.  Extra-hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling.

Authors:  Marina Kacevska; Andre Mahns; Rohini Sharma; Stephen J Clarke; Graham R Robertson; Christopher Liddle
Journal:  Pharm Res       Date:  2013-04-20       Impact factor: 4.200

Review 7.  Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression.

Authors:  Satyanarayana R Pondugula; Hanqing Dong; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-08       Impact factor: 4.481

8.  Metabolomics reveals that tumor xenografts induce liver dysfunction.

Authors:  Fei Li; Andrew D Patterson; Kristopher W Krausz; Changtao Jiang; Huichang Bi; Anastasia L Sowers; John A Cook; James B Mitchell; Frank J Gonzalez
Journal:  Mol Cell Proteomics       Date:  2013-05-01       Impact factor: 5.911

9.  A Semi-Physiologically Based Pharmacokinetic Model Describing the Altered Metabolism of Midazolam Due to Inflammation in Mice.

Authors:  Ninad Varkhede; Nita Patel; William Chang; Kenneth Ruterbories; M Laird Forrest
Journal:  Pharm Res       Date:  2018-06-21       Impact factor: 4.200

10.  Disrupted hepatic pentose phosphate pathway directly participates in and indirectly promotes CYP3A reduction: A new strategy for CYP3A-mediated drug hepatotoxicity.

Authors:  Jiali Liu; Xiaoliang Jin; Fang Zhou; Hongzhu Chen; Wenjie Wang; Yan Liu; Guangji Wang; Kun Hao; Jingwei Zhang
Journal:  Br J Pharmacol       Date:  2020-01-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.